Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Tactile Medical reported Q1 revenue of $75.3 million, up 23% year-over-year, driven by broad-based growth across its lymphedema and airway clearance product lines. The company achieved positive Adjusted EBITDA of $3.7 million compared to a loss in the prior year, prompting a modest raise in full-year 2026 revenue guidance to $360 million-$368 million.
Key figures
- Revenue
- $75.3 million
- Guidance
- FY2026 revenue $360M-$368M (raised from $357M-$365M), Adjusted EBITDA $49M-$51M
- Revenue Yoy
- 23%
- Net Loss
- $1.8 million
- Adjusted EBITDA
- $3.7 million
- Share Repurchase
- $1.1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.